|
WO2021067823A2
|
|
A new treatment for meibomian gland dysfunction
|
|
WO2020243496A1
|
|
A therapeutic approach for treating non-infectious ocular immunoinflammatory disorders
|
|
WO2020190848A1
|
|
Isolation, enrichment and expansion of cone progenitor cells and uses thereof
|
|
WO2020180865A1
|
|
Modulating neuroinflammation
|
|
WO2020097345A1
|
|
Therapeutic approaches for tissue reconstruction and wound healing treatment
|
|
WO2020081673A1
|
|
Bioadhesive for soft tissue repair
|
|
WO2019195450A1
|
|
Assessing visual function
|
|
WO2019178100A1
|
|
Predicting result reversals of glaucoma hemifield tests
|
|
US2021040167A1
|
|
Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
|
|
CA3093086A1
|
|
A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
|
|
EP3758657A1
|
|
System and method for treating meibomian gland dysfunction
|
|
WO2019169166A1
|
|
Visual field progression
|
|
WO2019165262A1
|
|
Measuring eye refraction
|
|
US2020397281A1
|
|
Measuring dark adaptation
|
|
WO2019099595A1
|
|
NANO-EMULSION OF CBFβ-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY
|
|
WO2019099560A1
|
|
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
|
WO2019075235A2
|
|
Expansion of field of view
|
|
WO2019070917A1
|
|
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
|
US2020246301A1
|
|
Compositions for the treatment of dry eye and methods of use thereof
|
|
CA3064711A1
|
|
Methods and compositions for reducing corneal endothelial cell loss
|
